Pembrolizumab is under clinical development by Merck and currently in Phase II for Anal Cancer. According to GlobalData, Phase II drugs for Anal Cancer have a 19% phase transition success rate (PTSR) ...
Pembrolizumab is under clinical development by Merck and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase transition ...
Amgen's bispecific antibody is more effective than chemotherapy and its Phase 3 trial is terminated early "Pharmaceutical Speed Reading Club" Astellas reaches $600 million cooperation, the first dom ...
INR:4954. deltin denzong reviews Medical dispute: Violation of diagnosis and treatment standards in treating fractures caused by traffic accidents, resulti ...
paripesa bet app The State Council issued a document to fully implement the sale of medicines in convenience stores Osimertinib prolongs disease-free survival in patients with early-stage EGFR-mutated ...